MA46440A - Solvate de diméthylsulfoxyde n-(3-[3-cyclopropyl-5-(2-fluoro-4-iodophénylamino)-6,8-diméthyl-2,4,7-trioxo-3,4,6,7-tétrahydro-2n-pyrido[4,3-d]pyrimidin-1-yl]-phényl)- cyclopropanecarboxamide utilisé en tant que inhibiteur de mek1/2 - Google Patents

Solvate de diméthylsulfoxyde n-(3-[3-cyclopropyl-5-(2-fluoro-4-iodophénylamino)-6,8-diméthyl-2,4,7-trioxo-3,4,6,7-tétrahydro-2n-pyrido[4,3-d]pyrimidin-1-yl]-phényl)- cyclopropanecarboxamide utilisé en tant que inhibiteur de mek1/2

Info

Publication number
MA46440A
MA46440A MA046440A MA46440A MA46440A MA 46440 A MA46440 A MA 46440A MA 046440 A MA046440 A MA 046440A MA 46440 A MA46440 A MA 46440A MA 46440 A MA46440 A MA 46440A
Authority
MA
Morocco
Prior art keywords
iodophenylamino
trioxo
mek1
cyclopropanecarboxamide
pyrido
Prior art date
Application number
MA046440A
Other languages
English (en)
Other versions
MA46440B1 (fr
Inventor
Mikhail Airatovich Chafeev
Vasily Gennadievich Ignatiev
Alexandre Vasilievich Ivachtchenko
Alexey Evgenievich Repik
Original Assignee
R Pharm Joint Stock Company R Pharm Jsc
Alexey Evgenievich Repik
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by R Pharm Joint Stock Company R Pharm Jsc, Alexey Evgenievich Repik filed Critical R Pharm Joint Stock Company R Pharm Jsc
Publication of MA46440A publication Critical patent/MA46440A/fr
Publication of MA46440B1 publication Critical patent/MA46440B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA46440A 2016-10-10 2016-12-12 Solvate de diméthylsulfoxyde n-(3-[3-cyclopropyl-5-(2-fluoro-4-iodophénylamino)-6,8-diméthyl-2,4,7-trioxo-3,4,6,7-tétrahydro-2n-pyrido[4,3-d]pyrimidin-1-yl]-phényl)- cyclopropanecarboxamide utilisé en tant que inhibiteur de mek1/2 MA46440B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2016139641A RU2627692C1 (ru) 2016-10-10 2016-10-10 N-{ 3-[3-циклопропил-5-(2-фторо-4-иодофениламино)-6,8-диметил-2,4,7-триоксо-3,4,6,7-тетрагидро-2Н-пиридо[4,3-d]пиримидин-1-ил]-фенил} -циклопропанкарбоксамида диметилсульфоксида сольват в качестве ингибитора МЕК1/2
PCT/RU2016/000862 WO2018070900A1 (fr) 2016-10-10 2016-12-12 Solvate de diméthylsulfoxyde n-{3-[3-cyclopropyl-5-(2-fluoro-4-iodophénylamino)-6,8-diméthyl-2,4,7-trioxo-3,4,6,7-tétrahydro-2n-pyrido[4,3-d]pyrimidin-1-yl]-phényl}- cyclopropanecarboxamide utilisé en tant que inhibiteur de mek1/2

Publications (2)

Publication Number Publication Date
MA46440A true MA46440A (fr) 2021-06-02
MA46440B1 MA46440B1 (fr) 2021-11-30

Family

ID=59641667

Family Applications (1)

Application Number Title Priority Date Filing Date
MA46440A MA46440B1 (fr) 2016-10-10 2016-12-12 Solvate de diméthylsulfoxyde n-(3-[3-cyclopropyl-5-(2-fluoro-4-iodophénylamino)-6,8-diméthyl-2,4,7-trioxo-3,4,6,7-tétrahydro-2n-pyrido[4,3-d]pyrimidin-1-yl]-phényl)- cyclopropanecarboxamide utilisé en tant que inhibiteur de mek1/2

Country Status (27)

Country Link
US (1) US10738049B2 (fr)
EP (1) EP3524601B1 (fr)
JP (1) JP6909299B2 (fr)
KR (1) KR102387288B1 (fr)
CN (1) CN110012668B (fr)
AU (1) AU2016426350B2 (fr)
BR (1) BR112019007223A2 (fr)
CA (1) CA3039524A1 (fr)
CO (1) CO2019004688A2 (fr)
CY (1) CY1125283T1 (fr)
DK (1) DK3524601T3 (fr)
EA (1) EA037939B1 (fr)
ES (1) ES2898026T3 (fr)
HR (1) HRP20211693T1 (fr)
HU (1) HUE056490T2 (fr)
LT (1) LT3524601T (fr)
MA (1) MA46440B1 (fr)
MD (1) MD3524601T2 (fr)
MX (1) MX2019004137A (fr)
PH (1) PH12019500721A1 (fr)
PL (1) PL3524601T3 (fr)
PT (1) PT3524601T (fr)
RS (1) RS62604B1 (fr)
RU (1) RU2627692C1 (fr)
SI (1) SI3524601T1 (fr)
WO (1) WO2018070900A1 (fr)
ZA (1) ZA201902861B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230293463A1 (en) 2022-03-17 2023-09-21 SpringWorks Therapeutics Inc. Treatment of cutaneous neurofibromas with Mirdametinib
CN114853754B (zh) * 2022-05-23 2023-04-18 云白药征武科技(上海)有限公司 一种硫代酰胺衍生物及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7378423B2 (en) * 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
CN101912400B (zh) 2004-06-11 2013-06-26 日本烟草产业株式会社 用于治疗癌症的5-氨基-2,4,7-三氧代-3,4,7,8-四氢-2H-吡啶并[2,3-d]嘧啶衍生物和相关化合物
TWI505828B (zh) * 2010-12-20 2015-11-01 葛蘭素史克智慧財產（第二）有限公司 新穎醫藥組成物
CA2889530A1 (fr) * 2012-10-25 2014-05-01 Glaxosmithkline Llc Combinaison
RU2605400C1 (ru) * 2015-11-13 2016-12-20 ЗАО "Р-Фарм" ПРОИЗВОДНЫЕ 1-(3-АМИНОФЕНИЛ)-6,8-ДИМЕТИЛ-5-(4-ИОД-2-ФТОР-ФЕНИЛАМИНО)-3-ЦИКЛОПРОПИЛ-1H,6H-ПИРИДО[4,3-d]ПИРИМИДИН-2,4,7-ТРИОНА В КАЧЕСТВЕ ИНГИБИТОРОВ МЕК1/2

Also Published As

Publication number Publication date
DK3524601T3 (da) 2021-11-08
SI3524601T1 (sl) 2022-02-28
EP3524601A4 (fr) 2020-03-11
WO2018070900A1 (fr) 2018-04-19
US20190233415A1 (en) 2019-08-01
KR20190062512A (ko) 2019-06-05
EA201900158A1 (ru) 2019-08-30
RS62604B1 (sr) 2021-12-31
PH12019500721A1 (en) 2019-12-02
ZA201902861B (en) 2021-06-30
JP2019531350A (ja) 2019-10-31
HUE056490T2 (hu) 2022-02-28
KR102387288B1 (ko) 2022-04-14
PT3524601T (pt) 2021-11-03
MA46440B1 (fr) 2021-11-30
HRP20211693T1 (hr) 2022-02-04
CY1125283T1 (el) 2023-03-24
JP6909299B2 (ja) 2021-07-28
ES2898026T3 (es) 2022-03-03
US10738049B2 (en) 2020-08-11
AU2016426350B2 (en) 2020-08-27
MX2019004137A (es) 2019-09-26
EP3524601A1 (fr) 2019-08-14
EA037939B1 (ru) 2021-06-09
CA3039524A1 (fr) 2018-04-19
RU2627692C1 (ru) 2017-08-10
EP3524601B1 (fr) 2021-10-13
LT3524601T (lt) 2021-12-27
MD3524601T2 (ro) 2022-02-28
CO2019004688A2 (es) 2019-05-21
CN110012668B (zh) 2021-11-26
AU2016426350A1 (en) 2019-05-30
CN110012668A (zh) 2019-07-12
PL3524601T3 (pl) 2022-03-21
BR112019007223A2 (pt) 2019-07-02

Similar Documents

Publication Publication Date Title
DK3436461T3 (da) Pyrrolotriazinforbindelser som tam-inhibitorer
DK3190113T3 (da) Pyrrolopyrimidinforbindelser anvendt som tlr7-agonist
EP3126893A4 (fr) Mesures de mise au point par métrologie de diffusiomètrie
FR3020680B1 (fr) Systeme d'evaluation de l'etat d'un pneumatique
EP3353744A4 (fr) Analyse d'image permettant de réaliser des mesures d'animaux comprenant une analyse d'image 3d
FR22C1058I1 (fr) Formulation de comprimé de 2-fluoro-n-méthyl-4-[7-(quinoline -6-ylméthyl) imidazo[1,2-b][1,2,4]triazine -2-yl]benzamide
DK3282240T3 (da) Lejeprøvestand
IL254512A0 (en) Test pieces of real material for training explosive detection dogs
FR3043034B1 (fr) Console munie d’accoudoirs articules comprenant un mecanisme de deverrouillage perfectionne
DK3487475T3 (da) Formulering til bløde anticholinerge analoger
GB201712253D0 (en) Images for query answers
FR3006437B1 (fr) Procede de calibration autonome d'un equipement inertiel utilise en mode statique
FR3055686B1 (fr) Systeme de canalisations avec detection de fuite
BR112016027229A2 (pt) falso pistão para prensa de extrusão
MA46440A (fr) Solvate de diméthylsulfoxyde n-(3-[3-cyclopropyl-5-(2-fluoro-4-iodophénylamino)-6,8-diméthyl-2,4,7-trioxo-3,4,6,7-tétrahydro-2n-pyrido[4,3-d]pyrimidin-1-yl]-phényl)- cyclopropanecarboxamide utilisé en tant que inhibiteur de mek1/2
BR112016018716A2 (pt) aparelho para medição.
FR3057334B1 (fr) Raccord rapide
EP3332237A4 (fr) Dispositif de déclenchement à double axe pour essai de pneu
FI11211U1 (fi) Puristinlaite
BR112016025075A2 (pt) formulação agroquímica.
HUP1700073A2 (en) Agrochemical solid formulation
PT3165576T (pt) Corantes poliméricos à base de poli(amidoaminas)
DK3283875T3 (da) Ultralydsinspektionsapparat til en lejekugle
BR112016020760A2 (pt) método e dispositivo para a detecção e avaliação de hiperemia reativa usando pletismografia segmentar.
ES1172459Y (es) Equipo de medicion de volumenes de productos de solidos y liquidos endispositivos de almacenamiento.